SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-290302
Filing Date
2023-12-07
Accepted
2023-12-07 07:00:53
Documents
12
Period of Report
2023-12-07
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d646901d8k.htm   iXBRL 8-K 21922
  Complete submission text file 0001193125-23-290302.txt   142611

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20231207.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20231207_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20231207_pre.xml EX-101.PRE 11257
6 EXTRACTED XBRL INSTANCE DOCUMENT d646901d8k_htm.xml XML 3349
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 231471052
SIC: 2834 Pharmaceutical Preparations